Related Jobs
-
Clinical Research Associate
Job Type: Permanent
Salary: € 22000.00 per annum
Location: Serbia -
Freelance Clinical Research Associate
Job Type: Contract
Salary: £ 3000.00 per hour
Location: Slovenia
Amgen reports 'significant' pre-emptive skin therapy results
30 Jun 2008
Clinical Research
Amgen says it has seen positive trial results for pre-emptive skin rash therapy in metastatic colorectal cancer (mCRC) patients.
It says skin rash is one of the most common side effects of epidermal growth factor receptor (EGFr) inhibitors such as panitumumab, which may be given to mCRC patients.
Pre-emptive treatment reduced the incidence rate of grade-two and greater skin toxicities by over 50 per cent without additional side effects when compared to reactive skin treatment, according to data presented at the World Congress on Gastrointestinal Cancer in Barcelona.
The incidence of grade-three or greater skin toxicities was found to be 62 per cent for reactive treatment and 29 per cent for the pre-emptive treatment.
David Chang, vice-president for oncology clinical development at Amgen, said that trial results showing skin rash may be controlled by a relatively simple pre-emptive treatment represent a significant advancement.
Earlier this month, Amgen revealed the appointment of Anna S Richo as senior vice-president for Worldwide Compliance, where she will head the division responsible for corporate compliance and business ethics at the company.
